Horizon Europe launches two new AMR-focused calls

Horizon Europe launches two new AMR-focused calls

  • 25/06/2021

The EU’s Research and Innovation funding programme, Horizon Europe, has launched its research calls for 2021-2022 with an investment of €14.7 billion from the European Commission. The AMR-focused calls are part of an innovation strategy that was published by the EU at the end of last year.

The novel plans of this EU Pharmaceutical Strategy include, among other topics, the development of Pull incentives for antimicrobials. Now, the two specific calls for AMR-related work have been released. The first one, HORIZON-HLTH-2021-IND-07-02 focuses on development, procurement and responsible management of new antimicrobials.

The second one, called HORIZON-HLTH-2021-DISEASE-04-05, seeks to create ‘A roadmap towards the creation of the European partnership on One Health antimicrobial resistance (OH AMR)’. Both calls are for the period 2021-2022, and both lay the groundwork for subsequent steps. In the below linked document, go to pages 77 and 153, respectively, to find out detailed information about the calls.

Read more: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-4-health_horizon-2021-2022_en.pdf